全球生物产业资本论坛(Global Bioindustry Capital Forum GBCF)

进入21世纪，生命科学和生物技术正在推动新的科技革命的形成，生物产业已经成为全球经济新的增长点并将在一些国家和地区成为支柱产业。生物技术的应用几乎遍及人类经济生活的各个领域，生物经济初露端倪。扩大社会对生物技术的认识，引导社会资源发展生物产业，已成为社会各界有识之士的共识。

当前，历史罕见的国际金融危机正给我国经济带来严重冲击。越来越多的人都把眼光聚焦于号称“继IT业后又一黄金领域”———生物产业。当前，生物能源，生物能源，生物医药，生健康科技等新型产业正在形成。如何抓住这新一轮的产业变革机遇，领跑21世纪“生物经济”时代？

全世界生物企业不断成长、壮大，北美是现代生物技术发展较早的地区，生物技术产业已具有一定规模，无论是在研究水平还是投资强度、还是在产业规模和市场份额上，北美地区均领先于世界。北美地区拥有一半的生物技术公司和一半的生物技术专利；仅美国就有340家上市生物技术公司，市值高达3300亿美元北美生物技术产品的销售额占全球生物技术产品市场的90%以上。北美生物科技仍然是全球生物科技的主流。

同时，北美地区的众多生物公司，因金融风暴导致资金大规模缩水、新药项目停滞、找不到有意向的投资者，或制药企业资金流断裂进而陷入泥沼。这也是为中国企业面临海外并购开创了的最佳时机。

◆高效率洽谈融资专案

◆全面收集资方信息

◆获取发展所需资金、技术和市场

◆寻求战略合作伙伴

◆高效率洽谈投资专案

◆全面收集投资项目信息

◆获取投资所需行业信息和产业项目

◆寻求战略合作伙伴

◆同业交流，拓展个人社交圈

◆了解全球资本市场热点

◆获得国内外金融服务/工具资讯

◆了解行业动态和发展趋势

◆探索融资机会

◆建立商业网络

由加拿大环球财经公司举办的国际金融投资博览会（中国区会展），07年和08年分别在上海、大连获得了圆满的成功。会展吸引了众多的中国公司、海外投资机构与金融服务商。国际金融投资博览会（中国区会展）每届活动参会的中国公司平均超过200家，来自海外的投资机构和金融服务商超过100家，两天会展平均吸引人数超过2000人。同时，每届会展安排一对一资本对接洽谈会400场，通过这些会谈使资本供求双方达到的快速对接的效果。

同时，每届会展都会云集来至北美、欧洲和香港等地的交易所和金融服务商，使参展公司和参观者可以有机会广泛且深入的了解海外金融市场和融资渠道。活动还通过举办数十场专业讲座促进参会者了解更多的资本市场资讯。

每届会展结束后，多家参会的中国企业都会在主办方和所有大会支持伙伴的协助下完成融资、上市和产品并购等工作。

Global Bioindustry Capital Forum--2009, co-hosted by Canada Global Finance and Bioon Group Inc., will be held on December 3rd in Grand Hyatt Shanghai hotel. The forum will invite reputable industrial experts, business leaders, international investors, and top scientists and researchers to give keynote speeches and discuss the developmental strategy of Chinese bioindustry from a deep perspective and multiple angles. They will analyze and provide constructive suggestions on topics such as “the development of global bioindustry”, “the influence of venture capital on bioindustry”, “multi-national merger and acquisition”, and “The opportunity of bio-pharmaceutical industry in the global financial crisis” etc. Meantime, the forum will bridge the business communication between enterprises from North America and China, facilitate the expansion of overseas business of Chinese corporations, and enhance the fast development of international bioindustry.

Focusing on the North America and China, the forum will bring a serial of business matching activities between Chinese and North American public and private firms under the principle of pragmatism and high-efficiency. There will be 20-30 listed companies and institutional investors from North America and 40-60 local enterprises and financial institutions in bioindustry. The GBCF will organize multiple forms of trading and cooperative negotiation activities on 80-100 selected intra- and international bio-industrial projects.

Since entering 21st century, the development of life sciences and biotechnology has been driving a revolution of sciences and technology. Bioindustry has already evolved into a new growth point for global economy, and will gradually become the pillar industry in some countries and regions. The application of biotechnology has touched virtually every aspects of human economy, indicating that bio-economy is starting to reveal its importance. Raising the social awareness of biotechnology, and allocating social resources to the development of bioindustry are becoming the consensus of respected personages with great vision from all social sectors.

Currently, the rarely confronted global financial crisis brings devastatingly impact on the economy of China. More and more investors direct their eyes to bioindustry, which is recognized as the next generation of golden industry after IT. Various branches of bioindustry, including biofuels and bio-energy, bio-medical and bio-pharmaceutical industry, and biological healthcare, are rapidly growing. Under this special circumstance, how can we grasp the opportunity for further expansion in this round of industrial revolution, and lead the wave of bio-economy in the 21st century?

Tracing its evolutionary history, modern bioindustry is originated in the region of North America. In the global background, North American region have a lead over the rest of the world in research, investment intensity, industry scale, and market share. Half of all the biological firms and patents in biotechnology are located in North America. In the United States alone, there are 340 listed biotechnology companies, whose total market value worth as high as 330 billion US dollars. And the service and product of biotechnology firms in North America occupy more than 90% of the global biological technology market. Therefore, the biotechnology in North America is still the mainstream of the global biotechnology. However, due to the global financial crisis, many biotechnology companies in North America are confronted with severe challenges, such as massive capital shrinkage, stagnation of research project, lack of investors, and breakdown of cash-flow chain. From another perspective, this global situation provides a good opportunity for the Chinese enterprises to start overseas merger and acquisition.
 

The benefits of participation

For public and private enterprises:
◆Find the best financing solutions within the shortest time
◆Collect the comprehensive information of excellent investors
◆Acquire venture capital, advanced technology and marketing expertise required for further development
◆Build your network with potential business partners
For investment institutions:
◆Find the best investment solutions within shortest time
◆Collect the comprehensive information of potential investment projects
◆Acquire latest information and promising projects of biotechnology industry
◆Build your network with potential business partners
For individuals:
◆Broaden your social cycle and communicate with your counterparts
◆Learn the spotlight of global capital market
◆Receive both domestic and international add-on financial service/tool information
◆Understand the latest development trend of biotechnology industry
◆Explore financing opportunity
◆Establish your business network